Consistent with this hypothesis, siRNAs knockdown of KRAS greatly reduced cytoplasmic EZH2 in A549 cells (Fig. 10a), which have mutant KRAS, and increased DLC1 protein in A549 and four other lung cancer lines with mutant KRAS (Fig. 10b–f). This evidence concerns the gene EZH2 and lung carcinoma.